Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenetics of irinotecan metabolism and transport: an update.

Toxicology in vitro : an international journal published in association with BIBRA - 1 Mar 2006

Smith Nicola F, Figg William D, Sparreboom Alex

Abstract excerpt

The anticancer agent irinotecan (CPT-11) is converted to SN-38, which is approximately 100 to 1,000-fold more cytotoxic than the parent drug. The pharmacokinetics of irinotecan are extremely complex and have been the subject of intensive investigation in recent years. Irinotecan is subject to extensive metabolism by various polymorphic enzymes, including CES2 to form SN-38, members of the UGT1A subfamily, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Phytogenic
Share to ATP Binding Cassette Transporter, Subfamily G, Member 2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Camptothecin

Share to Carboxylesterase

Share to Irinotecan

Share to Multidrug Resistance-Associated Protein 2

Share to Multidrug Resistance-Associated Proteins

Share to Prodrugs

Source

Identifiers

PMID: 16271446
DOI: 10.1016/j.tiv.2005.06.045

Genes

ABCB1
ABCC2
ABCG2
CES2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetics of irinotecan metabolism and transport: an update.PMID 16271446Read ↗

Pharmacogenetics of Irinotecan Disposition and Toxicity: A ReviewSemantic proximity Read ↗

OATP1B1 and tumour OATP1B3 modulate exposure, toxicity, and survival after irinotecan-based chemotherapy.Semantic proximity Read ↗

Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics.Semantic proximity Read ↗

Insights, challenges, and future directions in irinogenetics.Semantic proximity Read ↗

Pharmacokinetic and Pharmacogenetic Markers of Irinotecan Toxicity.Semantic proximity Read ↗

Pharmacogenetics of IrinotecanSemantic proximity Read ↗

Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1.Semantic proximity Read ↗

Pharmacogenetic Pathway Analysis of IrinotecanSemantic proximity Read ↗

Predictive Value of ABCC2 and UGT1A1 Polymorphisms on Irinotecan-Related Toxicities in Patients with Cancer.Semantic proximity Read ↗

Irinotecan, a key chemotherapeutic drug for metastatic colorectal cancer.Semantic proximity Read ↗

Clinical Pharmacogenetics of Irinotecan (CPT-11)Semantic proximity Read ↗

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.